These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32542581)

  • 1. Patients with systemic lupus erythematosus show increased proportions of CD19
    Zhu Q; Li Y; Zhang L; Wang M; Chen Z; Shi J; Li J; Li B; Li Z; Wang Y; Xie C
    Clin Rheumatol; 2021 Jan; 40(1):151-165. PubMed ID: 32542581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19
    Jia XY; Zhu QQ; Wang YY; Lu Y; Li ZJ; Li BQ; Tang J; Wang HT; Song CW; Xie CH; Chen LJ
    Clin Immunol; 2019 Jan; 198():89-99. PubMed ID: 30502542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The proportion of CD19
    Xie Z; Dai L; He H; Hong D; Wang Y; Xu W; Chen Z; Li B; Xie C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Feb; 40(2):148-157. PubMed ID: 38284256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus.
    Bijl M; Horst G; Limburg PC; Kallenberg CG
    Ann Rheum Dis; 2001 May; 60(5):523-6. PubMed ID: 11302879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of PD-1/PD-L1 signaling axis on the interaction between CD19
    Xie Z; Dai L; He H; Hong D; Tang H; Xu W; Chen Z; Wang H; Li B; Xie C; Wang Y
    Adv Rheumatol; 2023 Oct; 63(1):51. PubMed ID: 37848996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients.
    Shi H; Ye J; Teng J; Yin Y; Hu Q; Wu X; Liu H; Cheng X; Su Y; Liu M; Gu J; Lu T; Chen H; Zheng H; Sun Y; Yang C
    Arthritis Res Ther; 2017 Mar; 19(1):52. PubMed ID: 28274252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of PD-L1 on CD14⁺ monocyte in the peripheral blood of patients with systemic lupus erythematosus].
    Xie CH; Wang YY; Li ZJ; Tang J; Li BQ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Apr; 28(4):429-32. PubMed ID: 22482418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE).
    Spronk PE; Horst G; Van Der Gun BT; Limburg PC; Kallenberg CG
    Clin Exp Immunol; 1996 Jun; 104(3):446-53. PubMed ID: 9099929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells.
    Stefanski AL; Wiedemann A; Reiter K; Hiepe F; Lino AC; Dörner T
    Arthritis Rheumatol; 2019 Sep; 71(9):1539-1544. PubMed ID: 30919595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated CD19
    Ju B; Wang J; Mo L; Huang J; Hao Z; Lv X; Pu D; He L
    Int Immunopharmacol; 2022 Jan; 102():108403. PubMed ID: 34857478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19
    Xiong H; Tang Z; Xu Y; Shi Z; Guo Z; Liu X; Tan G; Ai X; Guo Q
    Adv Rheumatol; 2022 Dec; 62(1):48. PubMed ID: 36494762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus.
    El-Sayed ZA; Ragab SM; Khalifa KA; El Ashmawy RA
    Egypt J Immunol; 2009; 16(1):27-38. PubMed ID: 20726320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.
    Parodis I; Gomez A; Lindblom J; Chow JW; Sjöwall C; Sciascia S; Gatto M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD81 and CD19 as Marker of Activity in Systemic Lupus Erythematosus Disease.
    Abu-Zahab Z; Gad NM; Sabry S; Nassib SA
    Egypt J Immunol; 2017 Jun; 24(2):141-149. PubMed ID: 29528587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and significance of PD-1 on CD4(+); and CD8(+); T cells from the peripheral blood of patients with systemic lupus erythematosus].
    Wang Y; Xie C; Sun M; Chai J; Zhou Y; Chen Y; Tang J; Li B
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Sep; 29(9):962-5. PubMed ID: 24011159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
    Kraaij T; Arends EJ; van Dam LS; Kamerling SWA; van Daele PLA; Bredewold OW; Ray A; Bakker JA; Scherer HU; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
    Nephrol Dial Transplant; 2021 Jul; 36(8):1474-1483. PubMed ID: 32591783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.
    Liu MF; Weng CT; Weng MY
    J Biomed Biotechnol; 2009; 2009():406136. PubMed ID: 19759858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.